A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) as a prime-boost to GSK’s Chimp Adenovirus type 3 (ChAd3) Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).
{iframe}http://www.nasdaq.com/press-release/oxford-university-gsk-and-emergent-biosolutions-announce-initiation-of-a-prime-boost-study-of-ebol-20150513-00237{/iframe}